Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun’s Ranbaxy Buy Out Could Have Implications For Nexium Generics

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy’s ability to launch generic versions of AstraZeneca’s blockbuster Nexium in the U.S. on May 27 was uncertain already. Sun’s proposed $4 billion acquisition of Ranbaxy could further distract the troubled Indian generics firm from achieving that goal.

Advertisement

Related Content

Pfizer Expects OTC Nexium Will Launch With Market Exclusivity
Nexium Direct: AstraZeneca’s Ambitious Test Of Direct-To-Consumer Sales
AstraZeneca’s Promise To Investors: 10 New Drugs By 2020

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC087032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel